Compare Cassava Sciences Inc (FLNA) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Synopsys, Inc. — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Synopsys, Inc. trades at $410.06 (market cap $78.83B). The key difference: Synopsys, Inc. is far larger — about 1650.9× Cassava Sciences Inc's market cap, and Synopsys, Inc. is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SNPS | |
|---|---|---|
Market Cap | $47.75M | $78.83B |
Sector | Health | Technology |
52-Week High | $4.64 | $625.80 |
52-Week Low | $0.87 | $372.33 |
Enterprise Value | -$34.93M | $87.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Synopsys (SNPS) trades at $415.99, up 2.47% with strong technical momentum near resistance at $419. The stock shows robust fundamentals with consistent earnings beats (Q1 2026 EPS of $3.35 vs. $3.15 expected) and revenue growth to $7.05B in 2025. Recent developments include strategic AI partnerships with AMD and Microsoft, positioning the company at the forefront of chip design innovation.
Outlook remains positive with analyst consensus target of $559.50 suggesting 34% upside, though high P/E of 95.19 and aggressive cash flow investments in 2025-2026 present valuation and execution risks. The stock's bullish technical setup and strong institutional support outweigh near-term concerns for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
